Biofrontera AG Sponsored ADR Ending Cash

Ending Cash of BFAGY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Ending Cash growth rates and interactive chart.


Highlights and Quick Summary

  • Ending Cash for the quarter ending June 30, 2021 was $39.3 Million (a 238.37% increase compared to previous quarter)
  • Year-over-year quarterly Ending Cash increased by 151.33%
  • Annual Ending Cash for 2021 was $8.17 Million (a -56.76% decrease from previous year)
  • Annual Ending Cash for 2020 was $18.9 Million (a 51.77% increase from previous year)
  • Annual Ending Cash for 2019 was $12.5 Million (a -45.79% decrease from previous year)
  • Twelve month Ending Cash ending June 30, 2021 was $91.1 Million (a 33.48% increase compared to previous quarter)
Trailing Ending Cash for the last four month:
30 Jun '21 30 Jun '20 30 Sep '18
$91.1 Million $68.3 Million $73.4 Million
Visit stockrow.com/BFAGY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Ending Cash of Biofrontera AG Sponsored ADR

Most recent Ending Cashof BFAGY including historical data for past 10 years.

Interactive Chart of Ending Cash of Biofrontera AG Sponsored ADR

Biofrontera AG Sponsored ADR Ending Cash for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $39.31 $8.17
2020 $11.62 $18.9
2019 $12.45
2018 $24.58 $22.97
2017 $15.64 $16.45 $12.53
2016 $16.73 $16.74

Business Profile of Biofrontera AG Sponsored ADR

Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic